{"id":"comparator-placebo-metformin","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3–5","effect":"Metallic taste"},{"rate":"10–30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1431","moleculeType":"Small molecule","molecularWeight":"129.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing glucose uptake and utilization in muscle and adipose tissue. It may also improve insulin secretion from pancreatic beta cells and reduce intestinal glucose absorption. These combined effects lower blood glucose levels in patients with type 2 diabetes.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:07.018Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT03107884","phase":"EARLY_PHASE1","title":"Role of Metformin on Muscle Health of Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2019-08-01","conditions":"Muscle Atrophy, Insulin Resistance","enrollment":64},{"nctId":"NCT06042855","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2023-09-05","conditions":"Covid19","enrollment":3214},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT07131384","phase":"NA","title":"Interaction Between Inorganic Nitrate Supplementation and Metformin in Individuals With Prediabetes","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2025-09-01","conditions":"Males, Females, Sedentary","enrollment":24},{"nctId":"NCT07109700","phase":"PHASE2","title":"A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-04-30","conditions":"Type 2 Diabetes","enrollment":216},{"nctId":"NCT06649773","phase":"PHASE3","title":"The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-10-25","conditions":"Type 2 Diabetes","enrollment":137},{"nctId":"NCT06846138","phase":"NA","title":"Enhancing the Efficacy and Tolerability of Metformin by add-on Polyherbal Formulation: a Gut Microbiome Study","status":"ENROLLING_BY_INVITATION","sponsor":"Pauls Stradins Clinical University Hospital","startDate":"2025-03-01","conditions":"Diabetes Mellitus Type 2","enrollment":66},{"nctId":"NCT06860841","phase":"PHASE4","title":"Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Campus Bio-Medico University","startDate":"2025-01-10","conditions":"Type 2 Diabetes, Overweight and Obese Adults","enrollment":16},{"nctId":"NCT03331861","phase":"PHASE2","title":"Metformin in Heart Failure Without Diabetes","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-02-15","conditions":"Heart Failure","enrollment":6},{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT06140485","phase":"PHASE3","title":"A Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes Mellitus","status":"UNKNOWN","sponsor":"Natural Wellness Egypt","startDate":"2024-03","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT05297045","phase":"PHASE2","title":"A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes","status":"TERMINATED","sponsor":"Regor Pharmaceuticals Inc.","startDate":"2022-03-29","conditions":"Type 2 Diabetes Mellitus","enrollment":17},{"nctId":"NCT06128967","phase":"PHASE3","title":"A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial","status":"UNKNOWN","sponsor":"Cardresearch","startDate":"2023-10-18","conditions":"Long COVID-19 Syndrome, Chronic Fatigue Syndrome","enrollment":1500},{"nctId":"NCT04854512","phase":"PHASE3","title":"Investigational Study of Delayed Release Metformin","status":"SUSPENDED","sponsor":"Anji Pharma","startDate":"2021-05-18","conditions":"Diabetes Mellitus, Type 2","enrollment":675},{"nctId":"NCT04617275","phase":"PHASE2","title":"A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-06","conditions":"Diabetes, Obesity","enrollment":151},{"nctId":"NCT05422092","phase":"NA","title":"Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-20","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT04209075","phase":"PHASE2","title":"Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2020-03-10","conditions":"Diabetes","enrollment":6},{"nctId":"NCT05513729","phase":"","title":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-08-18","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT04089280","phase":"NA","title":"Probiotics in Metformin Intolerant Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2018-10-16","conditions":"Diabetes Mellitus, Type 2, Metformin Adverse Reaction","enrollment":37},{"nctId":"NCT01775813","phase":"PHASE4","title":"The Health Influences of Puberty (HIP) Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-06","conditions":"Obesity, Insulin Resistance, Gonadal Dysfunction","enrollment":104},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT00571519","phase":"PHASE3","title":"Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2007-11-14","conditions":"Type 2 Diabetes Mellitus","enrollment":94},{"nctId":"NCT00814294","phase":"PHASE2, PHASE3","title":"Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Diasome Pharmaceuticals","startDate":"2008-12","conditions":"Diabetes","enrollment":239},{"nctId":"NCT03359590","phase":"PHASE2","title":"Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2018-03-21","conditions":"Pharmacological Action","enrollment":20},{"nctId":"NCT02519543","phase":"PHASE3","title":"Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder","status":"COMPLETED","sponsor":"Cynthia Calkin","startDate":"2015-09","conditions":"Bipolar Disorder","enrollment":50},{"nctId":"NCT00970593","phase":"PHASE1","title":"Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09-02","conditions":"Diabetes Mellitus","enrollment":92},{"nctId":"NCT03235050","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-08-02","conditions":"Diabetes Mellitus, Type 2","enrollment":834},{"nctId":"NCT01717482","phase":"PHASE2","title":"Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2012-10","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":6},{"nctId":"NCT01353391","phase":"PHASE3","title":"Metformin in Women With Type 2 Diabetes in Pregnancy Trial","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2011-05-25","conditions":"Type 2 Diabetes","enrollment":500},{"nctId":"NCT03640221","phase":"PHASE4","title":"Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT03774108","phase":"PHASE4","title":"Metformin and Systemic Inflammation in HIV","status":"UNKNOWN","sponsor":"Hospital Civil de Guadalajara","startDate":"2018-12-15","conditions":"PreDiabetes, HIV-1-infection","enrollment":40},{"nctId":"NCT02496000","phase":"PHASE2","title":"Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Oramed, Ltd.","startDate":"2015-07-27","conditions":"Diabetes Type 2","enrollment":188},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02647320","phase":"PHASE2","title":"12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":298},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT02069379","phase":"PHASE4","title":"Endogenous Opioid Activity and Affective State in Insulin Resistant Women","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2014-07","conditions":"Depression, Insulin Resistance, Metabolic Syndrome","enrollment":42},{"nctId":"NCT00868790","phase":"PHASE2","title":"A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-24","conditions":"Type 2 Diabetes Mellitus","enrollment":118},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01462266","phase":"PHASE3","title":"Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-01-13","conditions":"Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT00698230","phase":"PHASE2","title":"Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2008-05","conditions":"Type 2 Diabetes","enrollment":302},{"nctId":"NCT02135549","phase":"NA","title":"Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin","status":"COMPLETED","sponsor":"Boston Therapeutics","startDate":"2014-05","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT02629627","phase":"PHASE2","title":"Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome","status":"COMPLETED","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2016-03","conditions":"Metabolic Syndrome","enrollment":104},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00830076","phase":"PHASE1","title":"A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT00813995","phase":"PHASE3","title":"A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-09","conditions":"Type 2 Diabetes Mellitus","enrollment":395},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00395343","phase":"PHASE3","title":"Sitagliptin Added-on to Insulin Study (0431-051)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-11","conditions":"Type 2 Diabetes Mellitus","enrollment":641},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00103857","phase":"PHASE3","title":"MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03-17","conditions":"Type 2 Diabetes Mellitus","enrollment":1208},{"nctId":"NCT01664624","phase":"PHASE1","title":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT02288273","phase":"PHASE4","title":"Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes","enrollment":239},{"nctId":"NCT00631488","phase":"PHASE2","title":"A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":146},{"nctId":"NCT00337610","phase":"PHASE3","title":"Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":190},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT01658501","phase":"PHASE2","title":"Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM","status":"COMPLETED","sponsor":"PhaseBio Pharmaceuticals Inc.","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":593},{"nctId":"NCT02548741","phase":"NA","title":"Evaluation of the Metformin Effect on Methylglyoxal in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT00479466","phase":"PHASE2","title":"Dose-Range Finding Study for MK0893 (0893-008)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Diabetes Mellitus, Type 2","enrollment":342},{"nctId":"NCT00541775","phase":"PHASE3","title":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus","enrollment":273},{"nctId":"NCT00975052","phase":"PHASE1","title":"A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT00543361","phase":"PHASE3","title":"Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-05","conditions":"Diabetes Mellitus, Type 2","enrollment":382},{"nctId":"NCT00814372","phase":"PHASE2","title":"Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2008-12","conditions":"Type 2 Diabetes Mellitus","enrollment":242},{"nctId":"NCT00767000","phase":"PHASE2","title":"Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-10","conditions":"Diabetes Mellitus, Type 2","enrollment":813},{"nctId":"NCT01438814","phase":"PHASE4","title":"Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":689},{"nctId":"NCT00740051","phase":"PHASE3","title":"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-08","conditions":"Diabetes Mellitus, Type 2","enrollment":227},{"nctId":"NCT00443755","phase":"PHASE2","title":"Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-08","conditions":"Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome","enrollment":28},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284},{"nctId":"NCT00743002","phase":"PHASE2","title":"A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2008-08","conditions":"Diabetes Mellitus, Type 2","enrollment":87},{"nctId":"NCT00473876","phase":"PHASE4","title":"Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2007-08","conditions":"Congestive Heart Failure, Insulin Resistance","enrollment":62},{"nctId":"NCT00145379","phase":"PHASE4","title":"The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2003-03","conditions":"Type 1 Diabetes Mellitus","enrollment":42},{"nctId":"NCT01423487","phase":"NA","title":"Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea","status":"WITHDRAWN","sponsor":"Central South University","startDate":"2011-08","conditions":"Weight Gain, Amenorrhea","enrollment":""},{"nctId":"NCT00684528","phase":"PHASE3","title":"A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2008-06","conditions":"Diabetes Type 2","enrollment":1000},{"nctId":"NCT00494312","phase":"PHASE4","title":"Safety Study of Pioglitazone Compared To Glyburide on Liver Function","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-10","conditions":"Diabetes Mellitus, Liver","enrollment":2120},{"nctId":"NCT00631007","phase":"PHASE2","title":"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator","status":"COMPLETED","sponsor":"InteKrin Therapeutics, Inc.","startDate":"2008-02","conditions":"Type 2 Diabetes Mellitus","enrollment":367}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":86,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["metformin"],"phase":"phase_3","status":"active","brandName":"Comparator: placebo metformin","genericName":"Comparator: placebo metformin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}